newsctDNAHNSCC
Liquid Biopsy Predicts Recurrence in HPV-Independent Head and Neck Cancer Months Before Imaging
By MedXY|Mar 23, 2026
A prospective study demonstrates that tumor-informed ctDNA-based minimal residual disease (MRD) testing significantly predicts recurrence and survival in HPV-independent HNSCC, offering a median five-month lead time over clinical detection
